Anthony S. Marucci has been serving as the President and Chief Executive Officer at Celldex Therapeutics Inc. since 2008. Celldex is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer and other serious diseases. Marucci has been instrumental in steering the company through various stages of growth and development, including the successful advancement of their clinical pipeline and the expansion of their therapeutic offerings. Before joining Celldex, Marucci held several leadership positions in the biotechnology industry. He was the President and CEO of Pharmacia Corporation's Oncology Business Unit, where he led the development and commercialization of several oncology drugs. Prior to that, he spent over a decade at Bristol-Myers Squibb, where he held various roles in sales, marketing, and business development. Marucci's extensive experience in the pharmaceutical and biotechnology sectors has been crucial in shaping Celldex's strategic direction and fostering innovation within the company. Under Marucci's leadership, Celldex has made significant strides in the development of its immunotherapy portfolio, particularly with its lead candidate, glembatumumab vedotin, which targets metastatic melanoma and breast cancer. Marucci's vision for the company includes a strong emphasis on research and development, as well as building strategic partnerships to enhance Celldex's capabilities and reach. His commitment to advancing novel treatments for patients with serious diseases has positioned Celldex as a leader in the field of targeted therapies.